ABTAbbott Laboratories New York Stock Exchange
Abbott Laboratories 100 Abbott Park Road Abbott Park IL, 60064-6400 http://www.abbott.comAbbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs.
- CEO: Miles D. White
- Employees: 99,000
- Sector: Healthcare
- Industry: Medical Devices
Latest news about the ABT
- PAHC vs. ABT: Which Stock Should Value Investors Buy Now?
PAHC vs. ABT: Which Stock Is the Better Value Option?View More →
- People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits
A new Harris Poll survey finds the majority of adults in the U.S. who exercise intensely understand the importance of maintaining hydration throughout a workout (93%) and that hydration is important for muscle recovery (89%), yet many have misconceptions about the type of hydration that may impact their ability to perform and recover optimally.View More →
- Abbott Earns First-of-Its-Kind Recommendation for High School STEM Interns to Receive College Credit
ABBOTT PARK, Ill., June 23, 2021 /3BL Media/ - High school students who complete Abbott's award-winning summer internship program are now eligible to receive college credit for the experience in a ...View More →
- New Strong Sell Stocks for June 22nd
ABT, BNL, ITRG, JAZZ, and MANU have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2021View More →
- Abbott's (ABT) Base Business Recovers, Lowered View Concerns
According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.View More →
- UPDATE 1-U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug
The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel. The justices turned away AbbVie's appeal and left intact the lower court's finding that its 2011 complaint against Perrigo was brought solely to delay Perrigo's proposed generic version of AndroGel. The Philadelphia-based 3rd U.S. Circuit Court of Appeals last year threw out a federal judge's order requiring AbbVie and partner Besins Pharmaceuticals to disgorge $448 million in profits to the Federal Trade Commission, but found that the judge had correctly determined that they had violated antitrust law.View More →
- The Zacks Analyst Blog Highlights: Abbott, Bank of America, PayPal, The Procter & Gamble Co and Boeing
The Zacks Analyst Blog Highlights: Abbott, Bank of America, PayPal, The Procter & Gamble Co and BoeingView More →
- Abbott (ABT) Stock Moves -1.16%: What You Should Know
In the latest trading session, Abbott (ABT) closed at $110.33, marking a -1.16% move from the previous day.View More →
- Top Research Reports for Abbott, Bank of America & PayPal
Top Research Reports for Abbott, Bank of America & PayPalView More →
- Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.View More →
- 10 Best Healthcare Stocks to Buy According to Hedge Funds
In this article, we will take a look at some of the best healthcare stocks to buy based on the data of over 860 hedge funds tracked by Insider Monkey. You can skip our detailed analysis of the healthcare industry and go directly to see 5 Best Healthcare Stocks to Buy According to Hedge Funds. […]View More →
- This Underappreciated Healthcare Stock Is on Sale: Should You Buy?
Medical devices giant Abbott Laboratories (NYSE: ABT) was on fire last year for one simple reason: Even though many of its business segments suffered due to the pandemic, the company established itself as one of the leaders in the COVID-19 testing market. Abbott Laboratories sold several hundred million coronavirus test kits last year, which helped keep the company's revenue and earnings afloat. In the fiscal year 2020, ending Dec. 31, Abbott Laboratories recorded sales of $34.6 billion -- an 8.5% year over year increase.View More →
- Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Abbott (ABT) closed at $110.48, marking a +0.52% move from the previous day.View More →
- Is Abbott Laboratories (ABT) Going to Burn These Hedge Funds?
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]View More →
- Corporate Bosses Make Well-Timed Stock Sales in SEC ‘Blind Spot’
(Bloomberg) -- When Abbott Laboratories chief Miles White cashed out $32 million of stock and options in 2019, shareholders had reason to shrug it off. Online regulatory filings said the sales were part of a “previously adopted plan” -- a sign they weren’t based on any current inside information.It turns out, the disposals that Monday had been set up the previous Friday. To learn that detail, investors would have to track down the plan he filed with the Securities and Exchange Commission by travView More →
- Lower Testing Shouldn’t Lower Quidel
When determining winners and losers in the 2020-2021 stock market, it is important not to overlook the companies that supply testing kits for COVID-19. The Quidel Corporation (QDEL) manufactures rapid healthcare diagnostic solutions, and received an FDA emergency use authorization for its antigen tests in early May 2020. (See QDEL stock analysis on TipRanks) Andrew Cooper of Raymond James Financial reported on the stock, stating that although COVID-19 is waning, the company can still stand to prView More →
- What Should Investors Make of Abbott's Reduced Full-Year Guidance?
COVID-19 testing ain't what it used to be. In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli talk about what investors should make of Abbott's reduced guidance. Keith Speights: Abbott, ticker there is ABT, had some other news that wasn't so good.View More →
- Abbott Declares 390th Consecutive Quarterly Dividend
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 45 cents per share.View More →
- Is Abbott Laboratories a Buy on the Dip?
Shares of top healthcare stock Abbott Laboratories (NYSE: ABT) are down 8% over the past month while the S&P 500 has been relatively steady, up by less than 1% during that period. Should investors considering adding Abbott's stock to their portfolios now that it is trading at a lower price, or is it likely headed for more of a decline? Why did Abbott reduce its earnings forecast?View More →
- Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
Abbott's (ABT) HeartMate 3 heart pump can significantly enhance quality of life and reduce adverse events.View More →